Géza Ambrus-Aikelin

Géza Ambrus-Aikelin is an accomplished scientist in the fields of immunology and inflammation, currently serving as the Head of Immunology & Inflammation at Genesis Therapeutics since April 2024. With previous leadership roles at Odyssey Therapeutics, Vividion Therapeutics, Jecure Therapeutics, and Janssen, Ambrus-Aikelin has a strong track record of advancing molecular drug discovery and developing innovative therapies for inflammatory diseases. Notable achievements include leading the development of small molecule inhibitors of the NLRP3 inflammasome and overseeing significant drug discovery programs across various companies. Ambrus-Aikelin's education includes a PhD in Structural Biochemistry from Eötvös Loránd University, an MA in Economics from Central European University, and an MS in Chemistry from Eötvös Loránd University.